Publication | Closed Access
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.
31
Citations
0
References
2013
Year
UrologyMalignant DiseaseMedicineCancer ManagementPhase Iii TrialAsco Daily NewsPathologyCancer Cell BiologyCancer PrognosisClinical OncologyPoor-prognosis Germ-cell TumorsCancer TreatmentOncologyRadiation OncologyCancer ResearchGetug 13Molecular OncologyFinal Text
LBA4500 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.